Last reviewed · How we verify
amiodarone amiodarone
Amiodarone blocks multiple cardiac ion channels (sodium, potassium, calcium, and beta-adrenergic) to slow electrical conduction and suppress abnormal heart rhythms.
Amiodarone blocks multiple cardiac ion channels (sodium, potassium, calcium, and beta-adrenergic) to slow electrical conduction and suppress abnormal heart rhythms. Used for Atrial fibrillation (maintenance of sinus rhythm and rate control), Ventricular tachycardia and ventricular fibrillation, Supraventricular tachycardia.
At a glance
| Generic name | amiodarone amiodarone |
|---|---|
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Drug class | Class III antiarrhythmic agent |
| Target | Potassium channels (hERG), sodium channels, beta-adrenergic receptors, calcium channels |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Amiodarone is a Class III antiarrhythmic agent that primarily blocks potassium channels to prolong the action potential duration and refractory period. It also has Class I, II, and IV properties due to its effects on sodium, beta-adrenergic, and calcium channels, making it a broad-spectrum antiarrhythmic. This multi-channel blockade makes it effective for suppressing both atrial and ventricular arrhythmias.
Approved indications
- Atrial fibrillation (maintenance of sinus rhythm and rate control)
- Ventricular tachycardia and ventricular fibrillation
- Supraventricular tachycardia
- Prevention of recurrent atrial fibrillation in patients with structural heart disease
Common side effects
- Pulmonary toxicity (pneumonitis, fibrosis)
- Thyroid dysfunction (hypo- or hyperthyroidism)
- Hepatotoxicity
- Photosensitivity and skin discoloration
- Corneal microdeposits
- Bradycardia
- QT prolongation
- Torsades de pointes
- Nausea and gastrointestinal upset
Key clinical trials
- Non-Invasive Programmed Stimulation (NIPS) to Guide the Subsequent VT Therapeutic Strategies (NA)
- Comparative Efficacy of 100-, 200-, & 400-mg Amiodarone in Patients With Paroxysmal AF Depending on Plasma Concentration (PHASE4)
- The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients (PHASE4)
- Pragmatic Amiodarone Trial to Reduce Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery (PHASE4)
- Catheter Ablation Versus Anti-arrhythmic Drugs for Ventricular Tachycardia (NA)
- Pharmacokinetics of Amiodarone in Children (NA)
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial Fibrillation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- amiodarone amiodarone CI brief — competitive landscape report
- amiodarone amiodarone updates RSS · CI watch RSS
- National Heart, Lung, and Blood Institute (NHLBI) portfolio CI